How has the acquisition of OneOncology impacted Cencora?

The acquisition of OneOncology, completed in December, enhances Cencora's capabilities within cancer care networks and has led to an updated fiscal year 2026 forecast with improved operating income growth expectations.

What is Cencora's updated fiscal year 2026 outlook?

Cencora now anticipates adjusted operating income growth between 11.5% and 13.5% for fiscal year 2026, an increase from its previous projection.

Home / Business and Economy / Cencora Surges on Specialty Drug Demand

Cencora Surges on Specialty Drug Demand

Q: What drove Cencora's first-quarter earnings beat?

Cencora's first-quarter earnings beat was driven by strong market demand for specialized medical treatments, including GLP-1 drugs and other specialty medications.

4 Feb

•

Summary

Cencora exceeded first-quarter profit expectations.
Demand for specialty drugs and GLP-1 therapies drove growth.
The company completed the $5 billion acquisition of OneOncology.

Cencora announced first-quarter financial results that exceeded analyst expectations, driven by strong market demand for specialized medical treatments. The company's performance was significantly bolstered by high sales volumes of GLP-1 drugs, used for diabetes and weight loss, and other specialty medications.

Further strengthening its market position, Cencora successfully completed the $5 billion acquisition of OneOncology in December. This strategic move enhances the company's capabilities within cancer care networks.

As a result of these developments, Cencora has updated its fiscal year 2026 forecast. The company now anticipates adjusted operating income growth to be between 11.5% and 13.5%, an upward revision from its previous projection. Cencora reaffirmed its full-year adjusted profit forecast, signaling continued confidence in its financial trajectory.

This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.